Novartis Ag (NVS) Profit After Tax Growth (1y) (2010 - 2025)
Novartis Ag (NVS) Profit After Tax Growth (1y) (2010 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 168.07% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -52.40% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -45.93% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 5.48% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -183.48% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 5.14% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 53.69% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -8.70% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 32.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 23.97% |
| Dec 31, 2024 | 10.16% |
| Sep 30, 2024 | 115.07% |
| Jun 30, 2024 | 40.09% |
| Mar 31, 2024 | 29.70% |
| Dec 31, 2023 | 109.84% |
| Sep 30, 2023 | 19.67% |
| Jun 30, 2023 | 36.70% |
| Mar 31, 2023 | -100.00% |
| Dec 31, 2022 | -100.00% |
| Sep 30, 2022 | -100.00% |
| Jun 30, 2022 | -41.45% |
| Mar 31, 2022 | -99.99% |
| Dec 31, 2021 | 538,478,260,769.57% |
| Sep 30, 2021 | 166,547,618,947.62% |
| Jun 30, 2021 | 55.06% |
| Mar 31, 2021 | 1,473,821,999,999,900.00% |
| Dec 31, 2020 | 87.76% |
| Sep 30, 2020 | -5.62% |
| Jun 30, 2020 | -72.54% |